Abstract

ABSTRACT FOR JUDGMENT
Required for ALL projects, used for judgment and should contain 500 words maximum.
ID: 102
Booth:
Project Title: TARGETED CANCER THERAPY STUDY: ANTIPROLIFERATIVE EFFECT OF CHR 6494
TRIFLUOROACETATE ON BREAST CANCER
Student(s)´s name(s): Ege Aral KARABULUT, Eylül Nehar KARABULUT
Project research area (according to MOSTRATEC website): Medicine and Health/ Diseases diagnosis and
treatment
Country: Turkey
ABSTRACT FOR JUDGMENT
(type here)
Breast cancer is a cancer type which is seen most commonly among women all
around the world. It is a complex and heterogeneous disease and is divided into
many subtypes (Cetin and Topcul, 2014). Cytotoxic chemotherapy has an
important part of cancer treatment, however it imposes some restrictions. As in
all types of cancers; surgery, radiotherapy and chemotherapy are the
conventional methods used in the treatment also in breast cancer. Since these
methods have some restrictions, it is difficult to treat the disease completely. In
recent years, new methods are being developed in order not only to overcome
these restrictions and but also to increase the therapeutic effectiveness at the
same (Topcul and Cetin, 2013). In this context, targeted treatments offer a
promising approach. The targeted medications used in the targeted treatments
describe new generation anticancer medications designed to be able to
intervene to specific molecular targets having a critical role particularly in tumor
growth and tumor development (Sawyers, 2004). Targeting not only cancer
cells but also healthy tissues generates many adverse effects that decrease the
life quality of patient. Together with, the conventional chemotherapy applied to
patients is palliative treatment as much as it is medical. In this study, it is aimed
to investigate the antiproliferative effects of CHR 6494 trifluoroacetate was
evaluated on MCF-7 cell line. For this purpose cell index values obtained from
xCELLigence RTCA (Real-Time Cell Analysis) DP instrument, mitotic index and
apoptotic index analysis among cell kinetic parameters were used. 10 microM,
25 microM, 50 microM, 75 microM and 100 microM concentrations of inhibitor
applied to cells 0-72 hours with using xCELLigence RTCA. Cell index values
obtained from xCelligence real-time cell analysis system showed that CHR
6494 trifluoroacetate has antiproliferative effects on MCF-7 cell lines
significantly. These values also showed that while 10 microM, 25 microM, 50
microM, 75 microM inhibitor doses have cytostatic effect, 10 microM has DNA
damaging effect on MCF-7 for 72 h. For mitotic and apoptotic index optimum
dose (100 microM) was used obtained from xCELLigence RTCA. While mitotic

index values decreased apoptotic index values increased significantly at time
dependent manner.
Key words: Targeted treatement, CHR 6494 trifluoroacetate, breast cancer,
MCF-7